Literature DB >> 15815932

Hepatic adenocarcinoma expressing inhibin in a young patient on oral contraceptives.

Eleni Vrettou1, Prodromos Hytiroglou, Nikolaos Sikas, Ioannis Soultoyannis, Zachary D Goodman.   

Abstract

A case of primary hepatic carcinoma is reported, which occurred in a 24-year-old woman with a 10-year history of oral contraceptive use, and demonstrated unique morphologic and immunohistochemical features. The tumor was located in the left hepatic lobe, measured 14 cm at its widest, and showed histologic heterogeneity. The neoplastic cells were mostly arranged in trabecular and pseudoglandular growth patterns simulating hepatocellular carcinoma; however, in focal areas, small cystic, organoid and tubular patterns predominated. Immunohistochemical stains showed a phenotype consistent with biliary differentiation (positive staining for cytokeratin 7, cytokeratin 19, carcinoembryonic antigen and CA 19-9 antigen). The tumor cells were negative for markers that would be suggestive of hepatocytic or neuroendocrine differentiation. Interestingly, they were positive for inhibin, a protein that is known to be expressed in sex cord-stromal tumors of the ovary, trophoblastic neoplasms and adrenal cortical tumors, but not in hepatic tumors. However, no definite evidence of gonadal stromal, trophoblastic, or adrenocortical differentiation was identified on extensive immunohistochemical work-up. In conclusion, this unique case may represent a rare variant of cholangiocarcinoma expressing inhibin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815932     DOI: 10.1007/s00428-005-1241-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  10 in total

1.  Immunohistochemical localization of inhibin-alpha in the placenta and gestational trophoblastic lesions.

Authors:  I M Shih; R J Kurman
Journal:  Int J Gynecol Pathol       Date:  1999-04       Impact factor: 2.762

2.  Inhibin is not an immunohistochemical marker for hepatocellular carcinoma. An example of the potential pitfall in diagnostic immunohistochemistry caused by endogenous biotin.

Authors:  J C Iezzoni; S E Mills; T J Pelkey; M H Stoler
Journal:  Am J Clin Pathol       Date:  1999-02       Impact factor: 2.493

3.  Expression of anti-OV6 antibody and anti-N-CAM antibody along the biliary line of normal and diseased human livers.

Authors:  M C Van Den Heuvel; M J Slooff; L Visser; M Muller; K P De Jong; S Poppema; A S Gouw
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma.

Authors:  M Y Altaee; P J Johnson; J M Farrant; R Williams
Journal:  Cancer       Date:  1991-11-01       Impact factor: 6.860

5.  Inhibin expression in ovarian tumors and tumor-like lesions: an immunohistochemical study.

Authors:  F Kommoss; E Oliva; A K Bhan; R H Young; R E Scully
Journal:  Mod Pathol       Date:  1998-07       Impact factor: 7.842

6.  A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors.

Authors:  A A Renshaw; S R Granter
Journal:  Mod Pathol       Date:  1998-12       Impact factor: 7.842

7.  Extrahepatic bile duct cancer and smoking, beverage consumption, past medical history, and oral-contraceptive use.

Authors:  S Yen; C C Hsieh; B MacMahon
Journal:  Cancer       Date:  1987-06-15       Impact factor: 6.860

8.  Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma.

Authors:  Sean K Lau; Sonam Prakash; Stephen A Geller; Randa Alsabeh
Journal:  Hum Pathol       Date:  2002-12       Impact factor: 3.466

9.  The alpha subunit of inhibin in adrenal cortical neoplasia.

Authors:  T J Pelkey; H F Frierson; S E Mills; M H Stoler
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

10.  The role of calretinin, inhibin, melan-A, BCL-2, and C-kit in differentiating adrenal cortical and medullary tumors: an immunohistochemical study.

Authors:  Paul J Zhang; Elizabeth M Genega; John E Tomaszewski; Teresa L Pasha; Virginia A LiVolsi
Journal:  Mod Pathol       Date:  2003-06       Impact factor: 7.842

  10 in total
  4 in total

1.  Hepatic carcinoma expressing inhibin: case report of a proposed novel entity and review of the literature.

Authors:  Antonia Syrnioti; Evangelia Athanasiou; Prodromos Hytiroglou
Journal:  J Pathol Transl Med       Date:  2022-06-15

2.  Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?

Authors:  K Frost; K Seir; A Lackner; M Grusch; B Grasl-Kraupp; R Schulte-Hermann; C Rodgarkia-Dara
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

3.  A Novel NIPBL-NACC1 Gene Fusion Is Characteristic of the Cholangioblastic Variant of Intrahepatic Cholangiocarcinoma.

Authors:  Pedram Argani; Doreen N Palsgrove; Robert A Anders; Steven C Smith; Carla Saoud; Regina Kwon; Lysandra Voltaggio; Naziheh Assarzadegan; Kiyoko Oshima; Lisa Rooper; Andres Matoso; Lei Zhang; Brandi L Cantarel; Jeffrey Gagan; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2021-11-01       Impact factor: 6.298

4.  A Cholangioblastic Variant of Cholangiocarcinoma.

Authors:  Kevin Verhoeff; Julinor Bacani; Christopher Fung; Laura A Canterbury
Journal:  ACG Case Rep J       Date:  2022-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.